The nasal mucosal late allergic reaction to grass pollen involves type 2 inflammation (IL-5 and IL-13), the inflammasome (IL-1β), and complement

Mucosal Immunology

Volumn 10, Issue 2, 2017, Pages 408-420

  Leaker, B R ^a   Malkov, V A ^b   Mogg, R ^b   Ruddy, M K ^b   Nicholson, G C ^a   Tan, A J ^c   Tribouley, C ^b   Chen, G ^b   De Lepeleire, I ^d   Calder, N A ^d   Chung, H ^a   Lavender, P ^e   Carayannopoulos, L N ^b   Hansel, T T ^c  

^a RESPIRATORY CLINICAL TRIALS LTD   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ST MARY S HOSPITAL   (United Kingdom)

^d MSD Europe Inc   (Belgium)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C5A; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; PLACEBO; PREDNISONE; SPHINGOLIPID ACTIVATOR PROTEIN 2; ALLERGEN; INFLAMMASOME; PLANT ANTIGEN;

ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; CURETTAGE; CYTOKINE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; EOSINOPHIL; GENE EXPRESSION; GRASS POLLEN; HUMAN; INFLAMMATION; NEUTROPHIL; NOSE MUCOSA; NOSE MUCUS; POLLEN ALLERGY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; UPREGULATION; WHOLE GENOME SEQUENCING; ADULT; DELAYED HYPERSENSITIVITY; DIET THERAPY; FEMALE; HYPERSENSITIVITY; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; POACEAE; POLLEN; TH2 CELL; YOUNG ADULT;

ADULT; ALLERGENS; ANTIGENS, PLANT; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; HYPERSENSITIVITY; HYPERSENSITIVITY, DELAYED; INFLAMMASOMES; INTERLEUKIN-13; INTERLEUKIN-1BETA; INTERLEUKIN-5; MALE; MIDDLE AGED; NASAL MUCOSA; POACEAE; POLLEN; PREDNISONE; TH2 CELLS; YOUNG ADULT;

EID: 85014537116     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2016.74     Document Type: Article

References (54)

1. Hansel, T.T., Johnston, S.L. & Openshaw, P.J. Microbes and mucosal immune responses in asthma. Lancet 381, 861-873 (2013).
2. Gauthier, M., Ray, A. & Wenzel, S.E. Evolving concepts of asthma. Am. J. Respir. Crit. Care Med. 192, 660-668 (2015).
3. Wheatley, L.M. & Togias, A. Clinical practice. Allergic rhinitis. N. Engl. J. Med. 372, 456-463 (2015).
4. Bourdin, A., Gras, D., Vachier, I.&Chanez, P. Upper airway 1: Allergic rhinitis and asthma: united disease through epithelial cells. Thorax 64, 999-1004 (2009).
5. Galli, S.J. & Tsai, M. IgE and mast cells in allergic disease. Nat. Med. 18, 693-704 (2012).
6. Choy, D.F. et al. Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. J. Immunol. 186, 1861-1869 (2011).
7. Peters, M.C. et al. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J. Allergy Clin. Immunol. 133, 388-394 (2014).
8. McKenzie, A.N. Type-2 innate lymphoid cells in asthma and allergy. Ann. Am. Thorac. Soc. 11 (Suppl 5), S263-S270 (2014).
9. Alam, R., Sim, T.C., Hilsmeier, K. & Grant, J.A. Development of a new technique for recovery of cytokines from inflammatory sites in situ. J. Immunol. Methods 155, 25-29 (1992).
10. Baumann, R. et al. Nasal levels of soluble IL-33R ST2 and IL-16 in allergic rhinitis: inverse correlation trends with disease severity. Clin. Exp. Allergy 43, 1134-1143 (2013).
11. Baumann, R. et al. Comparison of the nasal release of IL-4, IL-10, IL-17, CCL13/MCP-4, and CCL26/eotaxin-3 in allergic rhinitis during season and after allergen challenge. Am. J. Rhinol. Allergy 27, 266-272 (2013).
12. Chawes, B.L. et al. A novel method for assessing unchallenged levels of mediators in nasal epithelial lining fluid. J. AllergyClin. Immunol. 125, 1387-1389 (2010).
13. Folsgaard, N.V., Chawes, B.L., Bonnelykke, K., Jenmalm, M.C. & Bisgaard, H. Cord blood Th2-related chemokine CCL22 levels associate with elevated total-IgE during preschool age. Clin. Exp. Allergy 42, 1596-1603 (2012).
14. Scadding, G.W. et al. Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J. Immunol. Methods 384, 25-32 (2012).
15. Nicholson, G.C. et al. The effects of an anti-IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge. J. Allergy Clin. Immunol. 128, 800-807 (2011).
16. Proud, D. et al. Gene expression profiles during in vivo human rhinovirus infection: insights into the host response. Am. J. Respir. Crit. Care Med. 178, 962-968 (2008).
17. Poole, A. et al. Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease. J. Allergy Clin. Immunol. 133, 670-678 (2014).
18. Chung, K.F. Targeting the interleukin pathway in the treatment of asthma. Lancet 386, 1086-1096 (2015).
19. Moffatt, M.F. et al. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363, 1211-1221 (2010).
20. Trompette, A. et al. Allergenicity resulting from functional mimicry of a Tolllike receptor complex protein. Nature 457, 585-588 (2009).
21. Roschmann, K.I. et al. Timothy grass pollen extract-induced gene expression and signalling pathways in airway epithelial cells. Clin. Exp. Allergy 41, 830-841 (2011).
22. Blume, C. et al. Barrier responses of human bronchial epithelial cells to grass pollen exposure. Eur. Respir. J. 42, 87-97 (2013).
23. Diamant, Z. et al. Inhaled allergen bronchoprovocation tests. J. AllergyClin. Immunol. 132, 1045-1055 (2013).
24. Linden, M. et al. Immediate effect of topical budesonide on allergen challenge-induced nasal mucosal fluid levels of granulocyte-macrophage colony-stimulating factor and interleukin-5. Am. J. Respir. Crit. Care Med. 162, 1705-1708 (2000).
25. Leaker, B.R., Scadding, G., Jones, C.R. & Barnes, P.J. Using magnetic resonance imaging to quantify the inflammatory response following allergen challenge in allergic rhinitis. Immun. Inflamm. Dis 3, 445-454 (2015).
26. Gunawardana, GC et al. The effect of vitamin D supplementation on mucosal Il-5, MMP9 and cathelicidin after nasal allergen challenge with grass pollen. J Allergy Clin. Immunol. 137, AB73 (2016).
27. Bel, E.H. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371, 1189-1197 (2014).
28. Ortega, H.G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198-1207 (2014).
29. De, S.E. et al. Local immunoglobulin e in the nasal mucosa: clinical implications. Allergy Asthma Immunol. Res 7, 321-331 (2015).
30. Benson, M., Reinholdt, J. & Cardell, L.O. Allergen-reactive antibodies are found in nasal fluids from patients with birch pollen-induced intermittent allergic rhinitis, but not in healthy controls. Allergy 58, 386-392 (2003).
31. Sakaida, H., Masuda, S. & Takeuchi, K. Measurement of Japanese cedar pollen-specific IgE in nasal secretions. Allergol. Int. 63, 467-473 (2014).
32. Niederberger, V. et al. Antigens drive memory IgE responses in human allergy via the nasal mucosa. Int. Arch. Allergy Immunol. 142, 133-144 (2007).
33. Lambrecht, B.N. & Hammad, H. Allergens and the airway epithelium response: Gateway to allergic sensitization. J. Allergy Clin. Immunol. 134, 499-507 (2014).
34. Sim, T.C., Reece, L.M., Hilsmeier, K.A., Grant, J.A. & Alam, R. Secretion of chemokines and other cytokines in allergen-induced nasal responses: inhibition by topical steroid treatment. Am. J. Respir. Crit Care Med. 152, 927-933 (1995).
35. Dhariwal, J. et al. Nasal lipopolysaccharide challenge and cytokine measurement reflects innate mucosal immune responsiveness. PLoS ONE 10, e0135363 (2015).
36. Latz, E., Xiao, T.S. & Stutz, A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13, 397-411 (2013).
37. Holers, V.M. Complement and its receptors: new insights into human disease. Annu. Rev. Immunol. 32, 433-459 (2014).
38. Ricklin, D. & Lambris, J.D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190, 3831-3838 (2013).
39. Varsano, S., Kaminsky, M., Kaiser, M. & Rashkovsky, L. Generation of complement C3 and expression of cell membrane complement inhibitory proteins by human bronchial epithelium cell line. Thorax 55, 364-369 (2000).
40. Fukuoka, Y., Hite, M.R., Dellinger, A.L. & Schwartz, L.B. Human skin mast cells express complement factors C3 and C5. J. Immunol. 191, 1827-1834 (2013).
41. Fukuoka, Y. et al. Generation of anaphylatoxins by human beta-Tryptase from C3, C4, and C5. J. Immunol. 180, 6307-6316 (2008).
42. Andersson, M., Michel, L., Llull, J.B. & Pipkorn, U. Complement activation on the nasal mucosal surface-A feature of the immediate allergic reaction in the nose. Allergy 49, 242-245 (1994).
43. Jun, S.W. et al. Overexpression of the anaphylatoxin receptors, complement anaphylatoxin 3a receptor and complement anaphylatoxin 5a receptor, in the nasal mucosa of patients with mild and severe persistent allergic rhinitis. J. Allergy Clin. Immunol. 122, 119-125 (2008).
44. Bowser, C., Erstein, D.P., Silverberg, J.I., Nowakowski, M. & Joks, R. Correlation of plasma complement split product levels with allergic respiratory disease activity and relation to allergen immunotherapy. Ann. Allergy Asthma Immunol. 104, 42-49 (2010).
45. Schmudde, I., Laumonnier, Y. & Kohl, J. Anaphylatoxins coordinate innate and adaptive immune responses in allergic asthma. Semin. Immunol. 25, 2-11 (2013).
46. Couto, A.A. et al. Dysregulation of complement system and CD4 T cell activation pathways implicated in allergic response. PLoS ONE 8, e74821 (2013).
47. Shimizu, S. et al. Role of the coagulation system in allergic inflammation in the upper airways. Clin. Immunol. 129, 365-371 (2008).
48. Asaka, D. et al. Elevated levels of interleukin-33 in the nasal secretions of patients with allergic rhinitis. Int. Arch. Allergy Immunol. 158: (Suppl 1)) 47-50 (2012).
49. Savenije, O.E. et al. Association of IL33-IL-1 receptor-like 1 (IL1RL1) pathway polymorphisms with wheezing phenotypes and asthma in childhood. J. Allergy Clin. Immunol. 134, 170-177 (2014).
50. Dhariwal, J et al. Novel nasal sampling techniques identify ILC2s as important responders in asthma during nasal allergen challenge. Am J Resp Crit Care Med 193, A7546 (2016).
51. Scheiermann, C., Kunisaki, Y. & Frenette, P.S. Circadian control of the immune system. Nat. Rev. Immunol. 13, 190-198 (2013).
52. Gibbs, J. et al. An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action. Nat. Med 20, 919-926 (2014).
53. Hwang, J.W., Sundar, I.K., Yao, H., Sellix, M.T. & Rahman, I. Circadian clock function is disrupted by environmental tobacco/cigarette smoke, leading to lung inflammation and injury via a SIRT1-BMAL1 pathway. FASEB J 28, 176-194 (2014).
54. Greiff, L., Pipkorn, U., Alkner, U. & Persson, C.G. The nasal pool device applies controlled concentrations of solutes on human nasal airway mucosa and samples its surface exudations/secretions. Clin. Exp. Allergy 20, 253-259 (1990).